Merck & Co. Inc. (MRK)

89.10
NYSE : Health Technology
Prev Close 88.72
Day Low/High 88.51 / 89.53
52 Wk Low/High 70.89 / 89.24
Avg Volume 8.30M
Exchange NYSE
Shares Outstanding 2.55B
Market Cap 225.88B
EPS 2.30
P/E Ratio 41.65
Div & Yield 2.44 (2.48%)
Jim Cramer: Why Laggards Like Kohl's, Citi and CVS Can Rise Now

Jim Cramer: Why Laggards Like Kohl's, Citi and CVS Can Rise Now

I am neutral on this market, and only a cool off of the hottest stocks can justify a further advance.

Watch These 4 Japanese Drugmakers With Big Coming Events

Watch These 4 Japanese Drugmakers With Big Coming Events

Investors should keep tabs on these "focus events" from this quartet of U.S.-listed Japanese drugmakers that can make or break their treatments.

Merck & Co. Rated New Buy at Mizuo

3 Autopilot Funds for a High-Yield Portfolio

3 Autopilot Funds for a High-Yield Portfolio

This portfolio is built to hold up in any market, throw off a steady 8% dividend and pay monthly dividends, to boot.

AbbVie Joins Giant Acquisition Trend in Big Pharma With Allergan Deal

AbbVie Joins Giant Acquisition Trend in Big Pharma With Allergan Deal

The proposed, $63 billion transaction is the latest deal in an industry where it can be cheaper to buy the science of another company than develop products.

A Handful of Small Biotechs That Make for Merger Chatter

A Handful of Small Biotechs That Make for Merger Chatter

The names include a veterinary drug concern plus companies with successful drugs on the market.

Here's Why I'm Sticking With Merck

Here's Why I'm Sticking With Merck

The charts are saying MRK is ready to rise.

New Targets for Merck Stock as Charts Point Higher

New Targets for Merck Stock as Charts Point Higher

Investors and traders should approach MRK from the long side.

Here's How I'm Playing Salesforce.com Stock Now

Here's How I'm Playing Salesforce.com Stock Now

I am no longer as eager to sell these shares as when I discussed this merger pre-opening.

The Nasdaq A/D Line Peaked Months Ago: Danger Will Robinson

The Nasdaq A/D Line Peaked Months Ago: Danger Will Robinson

'It is not a healthy market when the generals are still going up and the troops are in retreat.'

Fibocall: Tuesday's Texts

Jim Cramer: These 7 True Laggards Have Caught Fire

Jim Cramer: These 7 True Laggards Have Caught Fire

These kinds of stocks are what goes up when there's so little left that hasn't moved that can still be worth buying.

Hey, Apple, Here's What This Shareholder Wants to Hear From You: Market Recon

Hey, Apple, Here's What This Shareholder Wants to Hear From You: Market Recon

We also dissect the S&P 500's record run, check out China's latest economic data and take a skeptical glance at an idea floated by a couple Fed officials.

News Surrounds 3 Small Biotechs, With a Merger Claiming One

News Surrounds 3 Small Biotechs, With a Merger Claiming One

Two companies in pet pharmaceuticals plan to combine, while two other concerns are worth a look based on developments in their respective spaces.

Be Careful With Healthcare Stocks Here

Be Careful With Healthcare Stocks Here

Especially when healthcare CEOs discus political issues with analysts and reporters.

Digging Down on the Dow 30

Digging Down on the Dow 30

Just 13 of the 30 Dow components are in clear uptrends.

Jim Cramer: Now We've Got FOBS, Fear of Big Sellers

Jim Cramer: Now We've Got FOBS, Fear of Big Sellers

Why are big institutions running and can you outrace them?

'Wonder Dogs' and 'Underdogs': 2 Hot Diggity Twists on the 'Dogs of the Dow'

'Wonder Dogs' and 'Underdogs': 2 Hot Diggity Twists on the 'Dogs of the Dow'

Selecting the creme de la creme of last year's top dividend dogs generated an average total return of 8.8%.

The Global Macro-Economic Picture, China Watch, Keys to Amazon: Market Recon

The Global Macro-Economic Picture, China Watch, Keys to Amazon: Market Recon

The real takeaway for AMZN for me, and the main reason that I am even in the name on a semi-permanent basis, is AWS.

The Technical Oracle of Delphi Says Merck Could Go Up or Down

The Technical Oracle of Delphi Says Merck Could Go Up or Down

How do the charts and indicators look ahead of their quarterly release?

Takeda Pharmaceutical CEO Talks Big Pharma Trends

Takeda Pharmaceutical CEO Talks Big Pharma Trends

One of pharma's biggest CEO's talks M&A action on the exchange.

Jim Cramer: Best and Worst of the Dow in 2018

Jim Cramer: Best and Worst of the Dow in 2018

And which stocks are still a buy into 2019.

Jim Cramer: The Long-Awaited Drug Company Consolidation Has Begun

Jim Cramer: The Long-Awaited Drug Company Consolidation Has Begun

And it is happening not a moment too soon.

Celgene Surges as Bristol-Myers Squibb Blockbuster Deal Begins Year With a Bang

Celgene Surges as Bristol-Myers Squibb Blockbuster Deal Begins Year With a Bang

Big pharma could be primed for an M&A Boom after Bristol-Myers Squibb's blockbuster deal for Celgene.

Merck Is My Top Stock Pick for 2019

Merck Is My Top Stock Pick for 2019

People will still take their medicine regardless of the state of the economy.

This 2019 Market Optimism Is Misplaced: Market Recon

This 2019 Market Optimism Is Misplaced: Market Recon

Take upbeat outlooks for equities with a grain of salt, and try these sectors to stay safe.

Jim Cramer: What to Buy in This Treacherous Market

Jim Cramer: What to Buy in This Treacherous Market

Look for the big-cap stocks that only come in on tough days -- and take advantage of their weakness at the open.

Jim Cramer: The Operative Term for This Tape Is Treacherous

Jim Cramer: The Operative Term for This Tape Is Treacherous

Use it to your advantage or don't use it at all.

3 Tips for Trading the Fed's More Dovish Stance

3 Tips for Trading the Fed's More Dovish Stance

Anticipating a weaker dollar thanks to the shift in the Fed, which stocks are most likely to benefit?

Pfizer Shares Jump on Monday After Company Signals Higher Price Push

Pfizer Shares Jump on Monday After Company Signals Higher Price Push

Pfizer pushes higher on price increases.